9.7 million people with world-class HMO electronic health records, globally unique genetic founder populations spanning Ashkenazi, Sephardi, Bedouin, and Ethiopian communities, Sheba Medical Center in the global hospital top 10, and the highest R&D-to-GDP ratio of any OECD nation.
Israel is a parliamentary democracy of approximately 9.7 million people occupying 22,072 km² on the eastern Mediterranean coast; bordered by Lebanon to the north, Syria to the northeast, Jordan to the east, and Egypt to the southwest. Despite its small size, Israel has established one of the world's most distinctive and productive clinical research ecosystems, driven by a combination of factors that no other country of comparable population replicates: universal mandatory health insurance through four competing Kupot Holim (HMOs) whose longitudinal population-scale electronic health records rank among the world's most complete; a radically genetically diverse population of five ancestrally distinct founder communities in a single regulatory jurisdiction; Sheba Medical Center consistently ranking in the global hospital top 10; and an innovation economy; the eponymous "Start-Up Nation"; whose R&D spending of approximately 5% of GDP is the highest of any OECD nation and whose biotech and pharmaceutical ecosystem includes Teva Pharmaceutical Industries (the world's largest generic pharmaceutical company, founded in Jerusalem) and hundreds of early-stage biotechnology companies conducting Phase I and first-in-human studies. The Tel Aviv metropolitan area (the Gush Dan region, ~4 million people) concentrates the majority of Israel's research infrastructure; Sheba Medical Center in Ramat Gan, Rabin Medical Center in Petah Tikva, Tel Aviv Sourasky Medical Center (Ichilov), and the main offices of Israel's global CRO and pharmaceutical industry community. Jerusalem provides the second research corridor through Hadassah Medical Center (a WHO Collaborating Centre renowned globally for haematology and bone marrow transplantation) and Shaare Zedek Medical Center. Haifa in the north is anchored by Rambam Health Care Campus and its Technion Faculty of Medicine affiliation. Beersheba in the Negev hosts Soroka University Medical Center and Ben-Gurion University's Faculty of Health Sciences; the research gateway to the Negev Bedouin population, one of the world's most intensively studied consanguineous communities for rare genetic disease research. Israel has been an ICH full member since 2016 and an OECD member since 2010, placing its regulatory and research standards firmly within the international highest tier.
Clinical trials are regulated by Israel's Ministry of Health (MOH) through its Pharmaceutical Administration; one of the Middle East's most sophisticated pharmaceutical regulatory bodies, fully aligned with ICH GCP E6(R2) and operating as an ICH member authority; clinical trial applications are reviewed and authorised by the MOH Pharmaceutical Administration alongside ethics approval through institutional Helsinki Committees; named for the Declaration of Helsinki and functioning as Israel's IRB-equivalent system; at each medical centre; all trials are registered in the Israeli National Clinical Trial Registry. The ICH membership and OECD affiliation mean that Israeli clinical trial data is accepted without question by FDA, EMA, PMDA, and all other ICH regulatory authorities; a regulatory equivalence that the GCT series' Latin American and Gulf Middle Eastern pages cannot uniformly claim. Israel's four HMOs; Clalit Health Services (~54% of citizens), Maccabi Healthcare Services (~26%), Meuhedet (~13%), and Leumit (~7%); collectively provide mandatory universal health coverage to essentially every Israeli citizen, tracking comprehensive health histories in longitudinal electronic databases that now span 30+ years of continuous population-level records; creating the most complete non-Nordic population health database in the world and the most efficient patient identification infrastructure of any research market covered in this series outside of Scandinavia.
Israel's population is defined by five ancestrally distinct major communities whose founder-effect genetics create the world's most pharmacogenomically diverse small-country research population: Ashkenazi Jews (approximately 35–40% of Jewish citizens); of Central and Eastern European origin, carrying well-characterised founder mutations including the three Ashkenazi BRCA1/2 variants (185delAG, 5382insC, 6174delT) that make approximately 1 in 40 Ashkenazi Jewish individuals a BRCA carrier, Gaucher disease type 1 founder mutations, familial dysautonomia, Canavan disease, and Bloom syndrome; whose pharmacogenomic profiles (CYP2D6, CYP2C19, CYP2C9 variant frequencies) reflect their Ashkenazi Eastern European ancestral isolation; Sephardi and Mizrahi Jews (approximately 40% of Jewish citizens); of North African, Middle Eastern, Mediterranean, and Iberian origin, carrying distinct founder mutations including the Sephardi/Mizrahi MEFV gene variants causing Familial Mediterranean Fever (FMF) and pharmacogenomic variant profiles distinct from both Ashkenazi and Arab reference populations; Bedouin Arabs of the Negev; an internally stratified tribal population of approximately 250,000–300,000, with one of the world's highest consanguineous marriage rates, harbouring some of the highest concentrations of rare autosomal recessive disorders documented in any population globally, studied extensively through Ben-Gurion University and Soroka Medical Center; Arab Israelis (approximately 21% of total population); Muslim and Christian Arab citizens concentrated in northern Israel (Galilee), the Negev, and mixed cities, with pharmacogenomic profiles reflecting Levantine Arab ancestry; and Ethiopian Jews (Beta Israel); approximately 160,000 Israelis of Ethiopian origin whose distinct Sub-Saharan African genetic ancestry creates pharmacogenomic profiles (including CYP2D6 ultra-rapid metaboliser prevalence from the CYP2D6*17 allele) found at very low frequencies in all other Israeli communities. National literacy approaches 99%; English is widely used in science, medicine, and research; Hebrew and Arabic are the official languages.
Israel's disease burden mirrors Southern European OECD countries in its NCD-dominant profile while carrying specific conditions substantially elevated above any European comparator. Cardiovascular disease is the leading cause of death (~28% of mortality). Cancer is the second leading cause; Israel's most globally distinctive oncological burden is BRCA-associated hereditary breast and ovarian cancer; with Ashkenazi Jewish women carrying BRCA mutations at rates approximately 10 times the global average, creating Israel's most commercially important oncology research niche for sponsors developing PARP inhibitors, targeted BRCA therapies, and cancer genetics interventions. Familial Mediterranean Fever affects approximately 1 in 200 Sephardi Jews and significant proportions of Arab Israeli communities; placing Israel among the world's highest FMF burden countries; and creating large patient cohorts for autoinflammatory disorder drug development. Type 2 diabetes (approximately 9–11% prevalence) and obesity (approximately 28% of adults) carry growing burden. Mental health disorders; including depression, anxiety, and PTSD; are significantly influenced by the Israeli security context, creating well-studied mental health populations through IDF (Israel Defence Forces) medical research and civilian HMO mental health services. Rare genetic diseases from the Bedouin population's consanguinity and the Jewish founder-effect communities create research concentrations that would require hemisphere-wide recruitment to match in any other single research jurisdiction.
Israel's HMO system and the COVID-19 vaccine proof; the world's most efficient population-based clinical research infrastructure outside Scandinavia: Since Israel's National Health Insurance Law (1995) mandated universal health coverage through four competing HMOs, essentially every Israeli citizen has been continuously documented in a longitudinal electronic health record capturing diagnoses, medications, laboratory values, imaging studies, hospitalizations, and in recent years genomic data; creating population-scale databases that now span 30+ years of comprehensive health history across 9.7 million people. The largest, Clalit Health Services (~4.5 million members), operates through the Clalit Research Institute one of the world's most extensively published population EHR databases, whose research output in NEJM, Lancet, JAMA, and BMJ has influenced global clinical guidelines across cardiovascular, oncology, diabetes, and infectious disease domains. Maccabi Healthcare Services Research Institute adds a further ~2.5 million longitudinal member records. The definitive proof of this system's global research value came on 20 February 2021, when the New England Journal of Medicine published the landmark paper demonstrating 95% effectiveness of the BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine in real-world conditions; authored by Israeli MOH and Pfizer researchers using Clalit's database. Pfizer chose Israel as its global real-world vaccine effectiveness partner specifically because the Clalit database could match vaccinated and unvaccinated individuals with 28-day longitudinal follow-up across 1.2 million matched pairs; a study that would have taken 12–18 months in the US or UK and that Israel produced in 6 weeks. For clinical trial sponsors, the HMO system delivers three irreplaceable research capabilities: exact pre-trial feasibility (query the database before activating a site to determine precise eligible patient numbers, treatment histories, and distribution); exceptional enrollment velocity (HMO members flagged as eligible can be systematically contacted through their treating physician, enabling Israel to enrol at per-capita rates that rival countries five times its size); and 30-year longitudinal follow-up for real-world evidence and safety signal detection that most markets cannot generate within a single regulatory submission's lifecycle.
Israel's research proposition combines the HMO system's enrollment efficiency and data depth; proven at global-defining scale in the COVID-19 Pfizer partnership; with the world's most concentrated rare genetic disease populations for oncology genetics and rare disease drug development, Sheba Medical Center's global top-10 research platform, and ICH full membership delivering regulatory data acceptance by every major global authority without the quality questions that occasionally accompany data from non-ICH markets.
MOH Pharmaceutical Administration with ICH full member status (since 2016) and OECD membership (since 2010); ICH GCP E6(R2)-compliant framework; Helsinki Committee institutional ethics review at all major medical centres; Israeli National Clinical Trial Registry; MOH approval timelines typically 2–3 months for standard Phase II–III applications; Israeli trial data accepted without qualification by FDA, EMA, PMDA, Health Canada, and all ICH regulatory authorities; EU Clinical Trial Regulation (CTR) compatibility enabling parallel EU-Israel trial submissions; no additional regulatory burden for sponsors already operating in ICH member jurisdictions.
Per-patient and operational costs substantially below US, Western European, and Australian equivalents; ILS-denominated operational costs competitive for USD/EUR-budgeted programs; HMO database pre-identification eliminates feasibility uncertainty and dramatically reduces screening costs; a sponsor can query the Clalit or Maccabi database before activating a single site to determine exact eligible patient numbers; small geography (~500km north-south) minimises internal trial logistics costs; HMO longitudinal follow-up reduces post-trial real-world evidence generation overhead; experienced CRO and SMO market in the Tel Aviv area with competitive pricing relative to EU comparators.
9.7M with 4-HMO longitudinal EHR spanning 30+ years; globally unique founder populations: Ashkenazi Jews (1-in-40 BRCA carrier; world's highest rate in a large population); Sephardi/Mizrahi Jews (FMF; world's largest accessible patient cohort); Negev Bedouin (world's most studied consanguineous rare disease population); Ethiopian Jewish (CYP2D6*17 ultra-rapid metaboliser frequency); Arab Israeli (Levantine pharmacogenomics); multi-founder-effect population enabling simultaneous pharmacogenomic studies across five distinct ancestries in 22,072 km²; COVID-19 vaccine real-world evidence track record proving enrollment velocity.
Sheba Medical Center (global top 10; largest hospital in the Middle East; most Phase I–IV active Israeli site); Hadassah Medical Center (haematology and bone marrow transplantation world reference; WHO Collaborating Centre); Rabin Medical Center Beilinson (major oncology, cardiovascular, haematology); Rambam Health Care Campus (Technion; northern Israel); HMO research institutes (Clalit Research Institute; Maccabi Healthcare Research Institute); Weizmann Institute of Science and Technion biomedical research ecosystem; Israel Innovation Authority-backed biotech ecosystem; major global CRO offices in Tel Aviv; Ben-Gurion Negev Bedouin rare disease research infrastructure.
Oncology; and specifically hereditary cancer genetics; is Israel's most globally defining research pillar, anchored by the Ashkenazi Jewish population's extraordinary BRCA carrier rate: with approximately 1 in 40 Ashkenazi Jews carrying a BRCA1 or BRCA2 founder mutation; a rate 10 times the global average; Israel provides the world's most concentrated BRCA-associated hereditary breast and ovarian cancer patient population for sponsors developing PARP inhibitors, BRCA-targeted therapies, cancer genetics interventions, and hereditary cancer prevention programs; Sheba Medical Center's oncology institutes, Hadassah's breast oncology programme, and Rabin Medical Center's oncology department are all deeply embedded in BRCA research with internationally published investigator communities. Rare and genetic diseases are Israel's second defining research pillar; spanning Gaucher disease (Israel has the world's largest Gaucher disease population due to Ashkenazi founder effects; Gaucher's treatment by enzyme replacement therapy was developed significantly through Israeli patient research), Familial Mediterranean Fever (the world's largest FMF-accessible research population in Sephardi and Arab Israeli communities; colchicine's definitive evidence in FMF came partly from Israeli clinical research), and the extraordinary rare disease concentrations in the Negev Bedouin community where Ben-Gurion University and Soroka Medical Center have built a global reference centre for autosomal recessive disorders of consanguineous populations. Haematology is Israel's third defining pillar, anchored by Hadassah Medical Center's pioneering role in bone marrow transplantation and the elevated haematological conditions in specific Israeli communities (thalassaemia in some Arab and Sephardi communities; sickle cell traits in Ethiopian Jewish populations). Cardiovascular medicine, CNS and neurology (including PTSD research from Israel's defence medical system and growing Alzheimer's and Parkinson's programs), metabolic disease, infectious disease (Israel's COVID-19 real-world evidence infrastructure remains active), and digital health real-world evidence (using HMO databases for pharmacoepidemiological research) complete a therapeutic portfolio whose breadth and per-capita depth is unmatched by any country in the GCT series of comparable population size.
The Tel Aviv metropolitan area (Gush Dan) dominates Israeli clinical research; Sheba Medical Center in Ramat Gan, Rabin Medical Center in Petah Tikva, Tel Aviv Sourasky (Ichilov) in central Tel Aviv, and Meir and Kaplan Medical Centers further south together account for the majority of Israel's commercial Phase II–IV trial activity. Jerusalem provides a deeply respected second corridor through Hadassah's internationally recognised research programme. Haifa anchors the north through Rambam, while Beersheba's Soroka Medical Center opens the unique Negev Bedouin rare disease research corridor that is accessible through no other institution in the world.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Sheba Medical Center (Tel HaShomer) | Ramat Gan | Israel's largest and most internationally recognised hospital; consistently ranked in the global top 10 hospitals by Newsweek and the largest medical centre in the Middle East; affiliated with Tel Aviv University's Sackler Faculty of Medicine and operating Israel's most active commercial Phase I–IV trial portfolio across oncology, haematology, cardiovascular, neurology, rare diseases, and metabolic disease; Sheba's ARC (Accelerate, Research, Collaborate) innovation centre connects global pharmaceutical and biotech companies to Sheba's investigator community in a structured commercial partnership model that is the most sophisticated of any Israeli institution; with multiple specialty institutes covering oncology (including hereditary cancer genetics), cardiac, neurological, and rare disease programmes, Sheba is the primary port of entry for international sponsors establishing their first Israeli clinical trial site relationship. |
| 02 | Rabin Medical Center; Beilinson Campus | Petah Tikva | One of Israel's largest and most research-active medical centres; affiliated with Tel Aviv University and comprising the Beilinson and Hasharon campuses; with Israel's most active oncology clinical trial portfolio outside Sheba; Rabin's Davidoff Cancer Center is a dedicated comprehensive cancer centre whose BRCA research programme, haematological malignancy trials (lymphoma, leukaemia, myeloma), and solid tumour Phase II–III portfolio are among the most internationally published in Israel; the Rabin Medical Center haematology department has been a pioneer in bone marrow transplantation, CAR-T cell therapy, and novel haematological treatment trials; its cardiovascular and metabolic disease departments maintain active commercial Phase II–III portfolios making Rabin Medical Center Israel's most multi-indication commercial trial hub after Sheba. |
| 03 | Tel Aviv Sourasky Medical Center (Ichilov) | Tel Aviv | Tel Aviv's central academic medical centre; located in the heart of the city and affiliated with Tel Aviv University; with an active Phase II–IV commercial trial portfolio across oncology, cardiovascular, neurology, gastroenterology, and metabolic disease; Tel Aviv Sourasky Medical Center's central location; serving Tel Aviv's large and cosmopolitan urban population; provides patient access to the full breadth of Israel's urban demographic diversity, including the significant Russian-Jewish immigrant community, the Arab and Bedouin patients attending Tel Aviv hospitals, and the Ashkenazi-dominant professional population of central Tel Aviv whose BRCA carrier rates create exceptional hereditary oncology enrollment opportunities; its oncology, neurology, and gastroenterology departments have been particularly active in commercial Phase II–III programmes. |
| 04 | Hadassah Medical Center (Ein Kerem) | Jerusalem | One of the world's most historically significant academic medical centres; affiliated with the Hebrew University-Hadassah Faculty of Medicine and a WHO Collaborating Centre; with a global reputation particularly in haematology (bone marrow transplantation, where Hadassah's Prof. Eliezer Rachmilewitz and others made landmark contributions), stem cell biology, and hereditary disease; Phase I–IV across haematology (myelodysplastic syndromes, aplastic anaemia, inherited bone marrow failure syndromes, haematological malignancies), oncology, rare genetic diseases (Gaucher disease; Israel's reference centre), immunology, and internal medicine; Hadassah's Ein Kerem campus serves Jerusalem's diverse Ashkenazi, Sephardi, Arab, and ultra-Orthodox patient communities; providing pharmacogenomically diverse enrollment from Israel's most culturally and ancestrally heterogeneous city. |
| 05 | Shaare Zedek Medical Center | Jerusalem | Jerusalem's second major academic research hospital; affiliated with the Hebrew University and carrying a long international research tradition; with active Phase II–III commercial trial activity across oncology, cardiovascular, haematology, gastroenterology, and internal medicine; Shaare Zedek's patient catchment from Jerusalem's large ultra-Orthodox Jewish community; a population with distinct genetic characteristics (elevated Ashkenazi founder condition frequencies within a community that maintains very high internal marriage rates, creating a sub-founder effect within the Ashkenazi founder population); creates research access to a pharmacogenomically distinct patient sub-community of particular interest for rare disease and oncology genetics sponsors; its Jerusalem location provides research access to the Sephardi, Mizrahi, and Arab patient demographics of Israel's capital complementary to Hadassah's more cosmopolitan academic catchment. |
| 06 | Rambam Health Care Campus | Haifa | Northern Israel's flagship academic medical centre; affiliated with the Technion Israel Institute of Technology Faculty of Medicine and consistently ranked among Israel's five most research-active medical institutions; with a Phase I–IV commercial trial portfolio across oncology, cardiovascular, haematology, oncogenetics, and internal medicine; Rambam's Technion affiliation creates a biomedical engineering and translational research culture that bridges device innovation, computational biology, and clinical trial execution; reflecting the Technion's position as Israel's pre-eminent engineering university; its Haifa location provides access to northern Israel's Arab, Druze, and Jewish patient communities; a demographically distinct research catchment from the Tel Aviv and Jerusalem medical centres; and its proximity to Lebanon and Jordan borders creates an experienced trauma and emergency medicine research tradition of relevance for wound care and emergency medicine trials. |
| 07 | Carmel Medical Center | Haifa | Haifa's second major academic hospital; affiliated with the Technion Faculty of Medicine through the Clalit HMO network and serving the Carmel mountain district of northern Haifa; with Phase II–III research activity across oncology, cardiovascular, endocrinology, and internal medicine; Carmel Medical Center's Clalit HMO affiliation provides structured research access to Clalit's longitudinal patient database in the northern Israel catchment, enabling the same pre-trial patient identification and HMO-facilitated enrollment that makes Clalit-affiliated hospitals throughout Israel consistently efficient in commercial Phase II–III program activation; its mixed Haifa patient demographic; encompassing Jewish communities (including significant Russian and Ethiopian immigrant populations), Arab Israeli citizens, and Druze families from the Carmel hills; creates pharmacogenomically diverse enrollment complementary to Rambam's academic research environment. |
| 08 | Soroka University Medical Center | Beersheba | The primary academic research centre for southern Israel and the institutional gateway to the world's most studied consanguineous rare disease population; affiliated with Ben-Gurion University of the Negev Faculty of Health Sciences and serving as the sole tertiary referral hospital for approximately 800,000 people in the Negev and southern Israel, including the estimated 250,000–300,000 Negev Bedouin Arab population; Soroka's rare genetic disease programme; developed over 40 years in collaboration with Ben-Gurion University's Genetics Institute and the National Institute of Human Genome Research; is the world's primary research centre for autosomal recessive conditions of consanguineous Bedouin origin; with hundreds of genetically distinct rare conditions characterised in Negev Bedouin pedigrees (many first described in Soroka publications), Soroka Medical Center is irreplaceable for any sponsor developing therapies for rare recessive conditions that require patient concentrations unavailable in any other single research institution globally. |
| 09 | Meir Medical Center | Kfar Saba | A major Clalit-affiliated academic hospital north of Tel Aviv; affiliated with Tel Aviv University through the Clalit HMO network; with Phase II–III research activity across oncology, cardiovascular, haematology, and internal medicine; Meir Medical Center's proximity to the Sharon region's dense suburban population; including large Ashkenazi and Russian-Israeli communities in Netanya, Ra'anana, and the surrounding coastal plain; provides research access to Ashkenazi-dominant patient demographics whose BRCA founder mutation carrier rates and other Ashkenazi genetic disease frequencies are among the highest of any Israeli hospital's catchment zone; its Clalit HMO affiliation enables pre-trial database queries identifying eligible BRCA carrier and other genetically-defined patient populations with the precision feasibility that distinguishes Israel's HMO system from every other MENA research market. |
| 10 | Kaplan Medical Center | Rehovot | A major academic hospital in Rehovot; home of the Weizmann Institute of Science; affiliated with the Hebrew University-Hadassah Faculty of Medicine through the Clalit network and positioned at the interface between Israel's most internationally prestigious basic science research institution (Weizmann) and clinical trial execution; Phase II–III activity across haematology, oncology, cardiovascular, and internal medicine; Kaplan Medical Center's proximity to the Weizmann Institute creates translational research partnership opportunities; including access to Weizmann's structural biology, chemical biology, and immunology research programmes; that are not available at any other clinical hospital in Israel's central region; its Clalit HMO affiliation provides structured patient access across Rehovot's large and scientifically sophisticated population (many residents are scientists, academics, and research professionals) with unusually high research participation literacy. |
| 11 | Hillel Yaffe Medical Center | Hadera | A major academic hospital in Hadera (central coastal Israel) serving the Hadera-Wadi Ara corridor; one of Israel's most ethnically diverse regions, where Jewish communities (including significant Yemenite-Jewish and Moroccan-Jewish Sephardi communities) and Arab Israeli communities (both Muslim and Christian) coexist in adjacent communities; with Phase II–III activity across internal medicine, cardiovascular, oncology, and haematology; Hillel Yaffe's regionally diverse patient catchment; encompassing Ashkenazi, Sephardi, and Arab Israeli patients in proportions that reflect the full diversity of Israel's central corridor population; creates multi-founder-effect pharmacogenomic enrollment opportunities within a single hospital research programme; an important mid-country research site for sponsors designing Israel multi-site Phase III networks that require patient coverage extending between the Tel Aviv and Haifa research corridors. |
| 12 | Assuta Medical Centers | Tel Aviv | Israel's largest private hospital group; owned by Maccabi Healthcare Services, the country's second-largest HMO; operating the Assuta Medical Center Tel Aviv and Assuta Ashdod University Hospital (affiliated with Ben-Gurion University) as Israel's most research-active private clinical institutions; Phase II–IV commercial trial activity across oncology, surgery, and internal medicine, with Assuta's specialisation in elective surgery and outpatient oncology creating distinctive patient access for sponsors whose protocols require planned surgical intervention or outpatient cancer treatment settings; the Maccabi HMO ownership provides Assuta with the same pre-trial patient identification database access as Clalit-affiliated hospitals; Maccabi's ~2.5 million members are queryable for trial eligibility using the same longitudinal EHR precision that defines Israel's HMO competitive advantage over every other MENA clinical research market. |
Israel's largest and most internationally recognised hospital; consistently ranked in the global top 10 hospitals by Newsweek and the largest medical centre in the Middle East; affiliated with Tel Aviv University's Sackler Faculty of Medicine and operating Israel's most active commercial Phase I–IV trial portfolio across oncology, haematology, cardiovascular, neurology, rare diseases, and metabolic disease; Sheba's ARC (Accelerate, Research, Collaborate) innovation centre connects global pharmaceutical and biotech companies to Sheba's investigator community in a structured commercial partnership model that is the most sophisticated of any Israeli institution; with multiple specialty institutes covering oncology (including hereditary cancer genetics), cardiac, neurological, and rare disease programmes, Sheba is the primary port of entry for international sponsors establishing their first Israeli clinical trial site relationship.
One of Israel's largest and most research-active medical centres; affiliated with Tel Aviv University and comprising the Beilinson and Hasharon campuses; with Israel's most active oncology clinical trial portfolio outside Sheba; Rabin's Davidoff Cancer Center is a dedicated comprehensive cancer centre whose BRCA research programme, haematological malignancy trials (lymphoma, leukaemia, myeloma), and solid tumour Phase II–III portfolio are among the most internationally published in Israel; the Rabin Medical Center haematology department has been a pioneer in bone marrow transplantation, CAR-T cell therapy, and novel haematological treatment trials; its cardiovascular and metabolic disease departments maintain active commercial Phase II–III portfolios making Rabin Medical Center Israel's most multi-indication commercial trial hub after Sheba.
Tel Aviv's central academic medical centre; located in the heart of the city and affiliated with Tel Aviv University; with an active Phase II–IV commercial trial portfolio across oncology, cardiovascular, neurology, gastroenterology, and metabolic disease; Tel Aviv Sourasky Medical Center's central location; serving Tel Aviv's large and cosmopolitan urban population; provides patient access to the full breadth of Israel's urban demographic diversity, including the significant Russian-Jewish immigrant community, the Arab and Bedouin patients attending Tel Aviv hospitals, and the Ashkenazi-dominant professional population of central Tel Aviv whose BRCA carrier rates create exceptional hereditary oncology enrollment opportunities; its oncology, neurology, and gastroenterology departments have been particularly active in commercial Phase II–III programmes.
One of the world's most historically significant academic medical centres; affiliated with the Hebrew University-Hadassah Faculty of Medicine and a WHO Collaborating Centre; with a global reputation particularly in haematology (bone marrow transplantation, where Hadassah's Prof. Eliezer Rachmilewitz and others made landmark contributions), stem cell biology, and hereditary disease; Phase I–IV across haematology (myelodysplastic syndromes, aplastic anaemia, inherited bone marrow failure syndromes, haematological malignancies), oncology, rare genetic diseases (Gaucher disease; Israel's reference centre), immunology, and internal medicine; Hadassah's Ein Kerem campus serves Jerusalem's diverse Ashkenazi, Sephardi, Arab, and ultra-Orthodox patient communities; providing pharmacogenomically diverse enrollment from Israel's most culturally and ancestrally heterogeneous city.
Jerusalem's second major academic research hospital; affiliated with the Hebrew University and carrying a long international research tradition; with active Phase II–III commercial trial activity across oncology, cardiovascular, haematology, gastroenterology, and internal medicine; Shaare Zedek's patient catchment from Jerusalem's large ultra-Orthodox Jewish community; a population with distinct genetic characteristics (elevated Ashkenazi founder condition frequencies within a community that maintains very high internal marriage rates, creating a sub-founder effect within the Ashkenazi founder population); creates research access to a pharmacogenomically distinct patient sub-community of particular interest for rare disease and oncology genetics sponsors; its Jerusalem location provides research access to the Sephardi, Mizrahi, and Arab patient demographics of Israel's capital complementary to Hadassah's more cosmopolitan academic catchment.
Northern Israel's flagship academic medical centre; affiliated with the Technion Israel Institute of Technology Faculty of Medicine and consistently ranked among Israel's five most research-active medical institutions; with a Phase I–IV commercial trial portfolio across oncology, cardiovascular, haematology, oncogenetics, and internal medicine; Rambam's Technion affiliation creates a biomedical engineering and translational research culture that bridges device innovation, computational biology, and clinical trial execution; reflecting the Technion's position as Israel's pre-eminent engineering university; its Haifa location provides access to northern Israel's Arab, Druze, and Jewish patient communities; a demographically distinct research catchment from the Tel Aviv and Jerusalem medical centres; and its proximity to Lebanon and Jordan borders creates an experienced trauma and emergency medicine research tradition of relevance for wound care and emergency medicine trials.
Haifa's second major academic hospital; affiliated with the Technion Faculty of Medicine through the Clalit HMO network and serving the Carmel mountain district of northern Haifa; with Phase II–III research activity across oncology, cardiovascular, endocrinology, and internal medicine; Carmel Medical Center's Clalit HMO affiliation provides structured research access to Clalit's longitudinal patient database in the northern Israel catchment, enabling the same pre-trial patient identification and HMO-facilitated enrollment that makes Clalit-affiliated hospitals throughout Israel consistently efficient in commercial Phase II–III program activation; its mixed Haifa patient demographic; encompassing Jewish communities (including significant Russian and Ethiopian immigrant populations), Arab Israeli citizens, and Druze families from the Carmel hills; creates pharmacogenomically diverse enrollment complementary to Rambam's academic research environment.
The primary academic research centre for southern Israel and the institutional gateway to the world's most studied consanguineous rare disease population; affiliated with Ben-Gurion University of the Negev Faculty of Health Sciences and serving as the sole tertiary referral hospital for approximately 800,000 people in the Negev and southern Israel, including the estimated 250,000–300,000 Negev Bedouin Arab population; Soroka's rare genetic disease programme; developed over 40 years in collaboration with Ben-Gurion University's Genetics Institute and the National Institute of Human Genome Research; is the world's primary research centre for autosomal recessive conditions of consanguineous Bedouin origin; with hundreds of genetically distinct rare conditions characterised in Negev Bedouin pedigrees (many first described in Soroka publications), Soroka Medical Center is irreplaceable for any sponsor developing therapies for rare recessive conditions that require patient concentrations unavailable in any other single research institution globally.
A major Clalit-affiliated academic hospital north of Tel Aviv; affiliated with Tel Aviv University through the Clalit HMO network; with Phase II–III research activity across oncology, cardiovascular, haematology, and internal medicine; Meir Medical Center's proximity to the Sharon region's dense suburban population; including large Ashkenazi and Russian-Israeli communities in Netanya, Ra'anana, and the surrounding coastal plain; provides research access to Ashkenazi-dominant patient demographics whose BRCA founder mutation carrier rates and other Ashkenazi genetic disease frequencies are among the highest of any Israeli hospital's catchment zone; its Clalit HMO affiliation enables pre-trial database queries identifying eligible BRCA carrier and other genetically-defined patient populations with the precision feasibility that distinguishes Israel's HMO system from every other MENA research market.
A major academic hospital in Rehovot; home of the Weizmann Institute of Science; affiliated with the Hebrew University-Hadassah Faculty of Medicine through the Clalit network and positioned at the interface between Israel's most internationally prestigious basic science research institution (Weizmann) and clinical trial execution; Phase II–III activity across haematology, oncology, cardiovascular, and internal medicine; Kaplan Medical Center's proximity to the Weizmann Institute creates translational research partnership opportunities; including access to Weizmann's structural biology, chemical biology, and immunology research programmes; that are not available at any other clinical hospital in Israel's central region; its Clalit HMO affiliation provides structured patient access across Rehovot's large and scientifically sophisticated population (many residents are scientists, academics, and research professionals) with unusually high research participation literacy.
A major academic hospital in Hadera (central coastal Israel) serving the Hadera-Wadi Ara corridor; one of Israel's most ethnically diverse regions, where Jewish communities (including significant Yemenite-Jewish and Moroccan-Jewish Sephardi communities) and Arab Israeli communities (both Muslim and Christian) coexist in adjacent communities; with Phase II–III activity across internal medicine, cardiovascular, oncology, and haematology; Hillel Yaffe's regionally diverse patient catchment; encompassing Ashkenazi, Sephardi, and Arab Israeli patients in proportions that reflect the full diversity of Israel's central corridor population; creates multi-founder-effect pharmacogenomic enrollment opportunities within a single hospital research programme; an important mid-country research site for sponsors designing Israel multi-site Phase III networks that require patient coverage extending between the Tel Aviv and Haifa research corridors.
Israel's largest private hospital group; owned by Maccabi Healthcare Services, the country's second-largest HMO; operating the Assuta Medical Center Tel Aviv and Assuta Ashdod University Hospital (affiliated with Ben-Gurion University) as Israel's most research-active private clinical institutions; Phase II–IV commercial trial activity across oncology, surgery, and internal medicine, with Assuta's specialisation in elective surgery and outpatient oncology creating distinctive patient access for sponsors whose protocols require planned surgical intervention or outpatient cancer treatment settings; the Maccabi HMO ownership provides Assuta with the same pre-trial patient identification database access as Clalit-affiliated hospitals; Maccabi's ~2.5 million members are queryable for trial eligibility using the same longitudinal EHR precision that defines Israel's HMO competitive advantage over every other MENA clinical research market.
Israel's Ministry of Health Pharmaceutical Administration; the ICH member national regulatory authority for pharmaceutical products and clinical trial authorisation; operating under the Patients' Rights Law, Public Health Ordinance, and ICH GCP E6(R2) standards; clinical trial applications are reviewed by the Pharmaceutical Administration in parallel with institutional Helsinki Committee ethics approval; MOH approval timelines of approximately 2–3 months for standard Phase II–III applications reflect the efficiency of Israel's compact regulatory system; ICH full membership since 2016 means Israeli clinical trial data is accepted by FDA, EMA, PMDA, and all ICH regulatory authorities without additional bridging requirements; the Helsinki Committee network at all major Israeli medical centres provides the institutional ethics oversight equivalent to IRBs in the US or Independent Ethics Committees in Europe.
Israel's national technology innovation funding authority; providing competitive grants and financial support across biomedical research, digital health, and pharmaceutical development; whose Life Science track has funded hundreds of Israeli clinical-stage biotech companies and supported the biomedical research infrastructure that makes Israel one of the world's most clinical-trial-active nations relative to its population; IIA's international technology partnerships; with the US, EU, India, and multiple other jurisdictions; facilitate the cross-border academic-commercial collaborations through which multinational pharmaceutical companies activate Israeli site relationships alongside Israeli biotech Phase I programmes; IIA's data on Israel's clinical research ecosystem provides the baseline market activity statistics that sponsors use for Israel feasibility assessments.
Israel's national bioethics advisory and policy body; under the auspices of the Ministry of Health; providing the national ethical framework within which institutional Helsinki Committees operate; INBC's policy positions on human subjects research, genetic privacy, and emerging biotechnology (including gene editing, stem cell therapy, and artificial intelligence in medicine) directly shape the institutional ethics review standards that govern commercial Phase II–III trial protocols at Israeli medical centres; Israel's bioethics framework; shaped by Jewish halakhic ethics, secular democratic values, and international bioethics principles; has produced some of the world's most nuanced and extensively debated policy positions on subjects including genomic data sharing, embryonic research, and novel therapeutic modalities.
The research arm of Clalit Health Services; Israel's largest HMO covering approximately 4.5 million members; and the institution that co-produced the landmark 2021 NEJM paper on COVID-19 vaccine effectiveness in partnership with Pfizer and Israel's MOH; the Clalit Research Institute operates one of the world's most extensively published population EHR databases, whose research output has shaped global clinical guidelines in cardiovascular medicine, oncology, diabetes, and infectious disease; for commercial Phase II–III trial sponsors, the Clalit database provides pre-trial patient identification, enrollment feasibility queries, HMO-facilitated investigator referral, and post-trial real-world follow-up capabilities that are the most efficient of any research market in the GCT series outside of Denmark or Sweden.
The research and innovation management centre of Sheba Medical Center; Israel's global top-10 hospital; whose ARC (Accelerate, Research, Collaborate) programme provides a structured commercial partnership pathway for international pharmaceutical and biotech companies seeking to activate clinical trials, co-develop biomarkers, establish Phase I units, or access Sheba's specialty investigator communities in oncology, haematology, cardiovascular, neurology, and rare disease; ARC's innovation model; connecting global sponsors directly to Sheba's senior investigators through a dedicated research commercialisation office; is the most sophisticated of any Israeli hospital's commercial research partnership infrastructure and the primary institutional entry point for first-time Israel clinical trial activations.
One of the world's leading multidisciplinary research institutions; consistently ranked among the top 10 research universities globally by Nature Index; whose departments of structural biology, chemical biology, immunology, plant and environmental sciences, and mathematics and computer science generate foundational drug discovery and biomedical research that feeds directly into Israeli clinical trial pipelines; Weizmann-originated research has been licensed to multiple international pharmaceutical companies and translated into clinical trials at Kaplan Medical Center, Sheba, and other nearby Israeli academic hospitals; for sponsors developing novel targeted therapies, immunomodulators, or precision medicine approaches, the Weizmann Institute provides Israel's most sophisticated basic science academic partnership environment.
The research arm of Maccabi Healthcare Services; Israel's second-largest HMO covering approximately 2.5 million members; operating a longitudinal EHR research database whose population scope and historical depth complement Clalit's database and together cover approximately 80% of the Israeli population in continuously updated longitudinal records; the Maccabi Research Institute's published pharmacoepidemiology research; including studies of vaccine effectiveness, medication adherence, and chronic disease outcomes across Maccabi's enrolled population; provides the methodological validation for real-world evidence strategies that commercial sponsors increasingly design into their Israeli clinical trial programs; Maccabi's database access through Assuta Medical Centers provides the private hospital complement to Clalit's public hospital research network.
Global CRO with major Israeli operations in Tel Aviv managing Phase I–IV programs across oncology (BRCA genetics, solid tumours, haematological malignancies), rare diseases (Gaucher, FMF, Bedouin conditions), cardiovascular, and metabolic disease; MOH Pharmaceutical Administration regulatory submission expertise and Helsinki Committee ethics application support across Sheba, Rabin, Ichilov, Hadassah, and Rambam; HMO database feasibility query coordination through Clalit and Maccabi research institute partnerships; established site monitoring networks across the Tel Aviv, Jerusalem, Haifa, and Beersheba medical centre clusters; real-world evidence design and execution using Israeli HMO databases for post-trial pharmacoepidemiology commitments.
International CRO with significant Israeli operations supporting Phase I–IV oncology genetics, rare disease, haematology, and cardiovascular programs; established investigator relationships across Sheba ARC, Rabin Davidoff Cancer Center, Hadassah haematology, and Soroka Bedouin rare disease programmes; specialist BRCA founder mutation and FMF trial management reflecting Israel's genetic disease research profile; MOH regulatory strategy for sponsors using Israel as the primary oncology genetics or rare disease anchor of global multi-site Phase II–III programmes; HMO database coordination for pre-trial patient identification and enrollment feasibility analysis.
Global CRO with Israeli operations providing Phase II–III trial management and MOH regulatory strategy across oncology, rare disease, haematology, cardiovascular, and CNS indications; established site networks across Tel Aviv, Jerusalem, Haifa, and Beersheba medical centre clusters; biostatistics and data management for Israeli-site trials with multi-founder-effect ancestry sub-group analysis across Ashkenazi, Sephardi, Bedouin, Ethiopian, and Arab Israeli patient populations; real-world evidence coordination using Clalit and Maccabi HMO databases for Phase IV pharmacoepidemiology and long-term safety follow-up design embedded within the Israeli mandatory insurance system's continuous longitudinal records.
International biopharmaceutical solutions company with Israeli operations providing integrated Phase I–IV clinical development services across oncology, rare disease, haematology, and cardiovascular indications; MOH submission expertise and Helsinki Committee ethics navigation across all major Israeli medical centre IRB systems; specialist hereditary cancer genetics and autoinflammatory disease trial management reflecting Israel's most distinctive research niches; HMO pre-identification database coordination for enrollment feasibility; international regulatory bridging support for sponsors filing Israeli Phase II–III data simultaneously with FDA, EMA, and PMDA submissions under ICH harmonised dossier standards.
Israel is the world's most research-efficient small country; a nation of 9.7 million people that punches at the per-capita research level of countries with populations three to five times its size, through a combination of assets that no other comparable research market in this series replicates. The HMO argument is foundational: four Kupot Holim providing mandatory universal coverage with 30+ years of comprehensive longitudinal EHR for essentially the entire Israeli population; a research infrastructure that Pfizer chose specifically when it needed the world's most rigorous real-world vaccine effectiveness data, producing the February 2021 NEJM paper that defined global COVID-19 vaccine policy from a 1.2-million-matched-pair Israeli database study delivered in six weeks. The genetic diversity argument is Israel's most scientifically distinctive: five ancestrally isolated founder communities in 22,072 km²; Ashkenazi Jews with the world's highest BRCA carrier rate in a large population (1 in 40), Sephardi and Mizrahi Jews with the world's most accessible FMF patient cohort, Negev Bedouins with the world's most studied rare autosomal recessive disease concentrations, Ethiopian Jews with African CYP2D6 pharmacogenomics, and Arab Israelis with Levantine ancestry; making Israel the only country in the Middle East and Mediterranean region where a single clinical trial activation simultaneously accesses five pharmacogenomically distinct reference populations for multi-ethnic PK bridging data. Sheba Medical Center's global top-10 ranking is Israel's institutional anchor: no other hospital in the Middle East, including Saudi Arabia's KFSHRC, consistently ranks in the global hospital top tier, and Sheba's ARC innovation centre's commercial partnership model is the most sophisticated sponsor engagement infrastructure of any research hospital between Berlin and Singapore. ICH full membership is the regulatory argument that makes everything else possible: Israeli Phase II data goes directly into FDA and EMA submissions without additional bridging requirements; a regulatory quality standard that Saudi Arabia, UAE, and every other Middle Eastern research market covered in this series has not yet achieved at ICH membership level. And for rare disease and oncology genetics sponsors specifically, Israel is not one option among many; it is the global reference location for BRCA founder mutations, Gaucher disease, Familial Mediterranean Fever, and Bedouin consanguineous rare diseases, with the institutional infrastructure (Hadassah, Soroka, Sheba, Rabin) to run the trials that these irreplaceable patient concentrations make possible.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.